The term rhinophyma is derived from the Greek words “rhis” and “phyma,” meaning nose and growth, respectively. The term was first used in 1845 by Ferdinand Von Hebra to describe a disfiguring thickening and overgrowth of nasal soft tissue [1, 2]. In this condition, hypertrophy of sebaceous glands leads to the development of a benign bulbous enlargement of the lower two-thirds of the nose with the presence of patulous follicles and telangiectasias. The pathogenesis of rhinophyma is not well understood but the condition represents the progression of untreated rosacea, a multifactorial condition with many exacerbating factors [3, 4]. Males are at significantly higher risk of the condition than women, with epidemiologic studies demonstrating a male to female ratio between 5:1 and 30:1 [1, 3, 5]. This may suggest that androgens play a role in rhinophyma development or progression. The disease is most commonly observed in Caucasian populations, especially those of Irish, English, and Scandinavian descent and among individuals with particularly fair skin. Development of rhinophyma typically occurs in the fifth to seventh decade of life, with the earliest signs being the appearance of dilated pores and erythema on the nasal tip [1, 3].